Northwest Biotherapeutics, Inc. /
Advent BioServices Ltd.
Northwest Biotherapeutics completes Advent BioServices purchase
Source for the buyer and target: Northwest Biotherapeutics Inc
For the buyer and target.
“As previously announced, on October 24, 2025 (the “Closing Date”), Northwest Biotherapeutics, Inc. (the “Company”) completed the acquisition of Advent BioServices Ltd. (“Advent”), a United Kingdom-based contract development and manufacturing organization (CDMO), from Toucan Holdings LLC (the “Seller”), pursuant to an acquisition agreement dated as of August 27, 2025.”
Published 7 Apr 2026
Open the sourceWhat happened
Northwest Biotherapeutics has finished buying Advent BioServices, a UK-based manufacturing partner that previously provided development, manufacturing, cryostorage and distribution services for its DCVax product platform. Advent is now a wholly owned subsidiary. [01]
The purchase price is about $1.9 million, with the balance of accounts payable also settled in installments over two years, and the deal was a related party transaction tied to the company's chairperson and CEO, Linda Powers. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Northwest Biotherapeutics completes Advent BioServices purchase
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly